^
Association details:
| Biomarker: | BRCA1 mutation |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | paclitaxel (Bcl2 inhibitor, Tubulin polymerization promoter) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
…NCCN Panel has included taxanes (paclitaxel), anthracyclines (doxorubicin and liposomal doxorubicin), anti-metabolites (capecitabine and gemcitabine), microtubule inhibitors (eribulin and vinorelbine), platinum agents for patients with triple negative tumors and germline BRCA 1/2 mutations.
